{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-031280","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-09-28T11:00:14+00:00","discovered_at":"2026-09-28T11:05:01.048348+00:00","generated_at":"2026-10-12T13:29:50.994025+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Moleculin publishes peer-reviewed Annamycin cardiac safety analysis: no cardiotoxicity in 90 patients across 5 trials","bullets":["Pooled analysis of 5 trials (3 AML, 2 metastatic STS): 90 patients treated, paired echocardiographic data for 78; mean LVEF 60.6% at baseline vs 60.0% post-treatment (p=0.84).","No association between cumulative Annamycin dose or patient age and LVEF change; serial ECGs, troponin I/T and global longitudinal strain showed no treatment-related cardiotoxicity.","Median cumulative Annamycin dose was 660 mg/m2, exceeding conventional anthracycline lifetime limits; analysis independently reviewed by a Cleveland Clinic cardio-oncology laboratory.","CEO Walter Klemp said the absence of detectable cardiac toxicity beyond traditional dose thresholds supports continued development of Annamycin as a potentially safer anthracycline.","Annamycin is currently being evaluated in Moleculin's MIRACLE clinical development program for relapsed or refractory AML."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-031280","json":"https://secwatch.observer/filing/0001437749-26-031280.json","markdown":"https://secwatch.observer/filing/0001437749-26-031280.md","text":"https://secwatch.observer/filing/0001437749-26-031280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926031280/0001437749-26-031280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926031280/mbrx20260925_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:29:50.994025+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}